Stratifying Disease Progression in Patients With Cardiac ATTR Amyloidosis
Adam Ioannou(MACOM (United States)), Marianna Fontana(Johnson & Johnson (United States)), Alberto Cipriani(Azienda Ospedale - Università Padova), Simone Longhi(Azienda USL di Bologna), Yael Lustig(University College London), Helen J. Lachmann(Royal Free London NHS Foundation Trust), Michele Emdin(Scuola Superiore Sant'Anna), Laura De Michieli(University of Padua), Lucia Venneri(MACOM (United States)), Philip N. Hawkins(The Royal Free Hospital), Giuseppe Vergaro(Scuola Superiore Sant'Anna), Christian Nitsche(Medical University of Vienna), Mattia Zampieri(Azienda Ospedaliero-Universitaria Careggi), Rishi Patel(MACOM (United States)), Scott D. Solomon(Brigham and Women's Hospital), Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Carol Whelan(Boston University), Ahmad Masri(Oregon Health & Science University), Ashutosh Wechalekar(Boston University), Michael Poledniczek(Medical University of Vienna), Yousuf Razvi(MACOM (United States)), Aldostefano Porcari(University of Trieste), Muhammad U. Rauf(MACOM (United States)), Francesco Cappelli(Fondazione Toscana Gabriele Monasterio), Alberto Aimo(Scuola Superiore Sant'Anna), Ana Martinez–Naharro(Children's Cancer and Leukaemia Group), Eugenia Villanueva(University College London), Federica Colio(Azienda Ospedaliero-Universitaria Careggi), Aviva Petrie(Eastman Dental Hospital)
Cited by 81
Related Papers
Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology
|Journal of the American Society of Echocardiography|2005|11.3k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
|New England Journal of Medicine|2022|2.6k
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
|New England Journal of Medicine|2003|2.5k